<DOC>
	<DOCNO>NCT00581854</DOCNO>
	<brief_summary>rituximab modify ( hyperCVAD ) administer every 28 day 4-6 cycle follow rituximab maintenance therapy consist four weekly dos every six month two year</brief_summary>
	<brief_title>Phase 2 Hyper-CVAD/Rituximab Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>rituximab modify hyperfractionated cyclophosphamide , vincristine doxorubicin , dexamethasone ( hyperCVAD ) administer every 28 day 4-6 cycle follow rituximab maintenance therapy consist four weekly dos every six month two year</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Untreated mantle cell lymphoma Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>untreated mantle cell lymphoma</keyword>
</DOC>